scholarly journals Sequential fluorescence in situ hybridisation analysis for cryptic t(11;14)(q13;q32) in mantle cell lymphoma

2006 ◽  
Vol 134 (5) ◽  
pp. 452-452 ◽  
Author(s):  
Sophie Gazzo ◽  
Jean M. Schiano de Colella ◽  
Evelyne Callet-Bauchu
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
In Situ Hybridisation ◽  
Fluorescence In Situ Hybridisation ◽  
Mantle Cell ◽  
Hybridisation Analysis

Complex analysis of cyclin D1 expression in mantle cell lymphoma: two cyclin D1-negative cases detected

2009 ◽  
Vol 62 (10) ◽  
pp. 948-950 ◽  
Author(s):  
L Stefancikova ◽  
M Moulis ◽  
P Fabian ◽  
I Falkova ◽  
I Vasova ◽  
...  
Keyword(s):  
Cyclin D1 ◽  
Mantle Cell Lymphoma ◽  
Complex Analysis ◽  
Cell Lymphoma ◽  
In Situ Hybridisation ◽  
D1 Protein ◽  
Fluorescence In Situ Hybridisation ◽  
Cyclin D2 ◽  
Mantle Cell ◽  
High Level

Background and Aim:The cytogenetic and diagnostic hallmark of mantle cell lymphoma (MCL) is translocation t(11;14)(q13;q32), resulting in overexpression of cyclin D1. Cyclin D1 expression was analysed in 32 cases of MCL.Methods:The t(11;14) translocation was detected by fluorescence in situ hybridisation, level of cyclin D1 mRNA by competitive RT-PCR, and level of cyclin D1 and D2 proteins by immunohistochemistry and/or immunoblotting.Results:In 30 cases, the presence of translocation t(11;14), a high level of cyclin D1 mRNA, and a high level of the cyclin D1 protein were confirmed. Two cyclin D1-negative cases overexpressing cyclin D2 were detected by immunoblotting.Conclusions:There are rare cyclin D1-negative cases of MCL overexpressing cyclin D2. Anti-cyclin D1 antibodies with low specificity can bind both cyclin D1 and cyclin D2, thus providing false cyclin D1-positive signals in immunohistochemical analysis.

scholarly journals HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1150
Author(s):  
Magda Zanelli ◽  
Luca Stingeni ◽  
Maurizio Zizzo ◽  
Giovanni Martino ◽  
Francesca Sanguedolce ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Rare Event ◽  
Castleman Disease ◽  
Axillary Lymph ◽  
Tnf Inhibitor ◽  
Dermatopathic Lymphadenitis ◽  
Multicentric Castleman Disease ◽  
Mantle Cell

A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and systemic medications including prednisolone, acitretin, anti-IL17 (ixekizumab), TNF inhibitor (adalimumab), anti-IL23 (guselkumab), methotrexate, cyclosporine, and phosphodiesterase 4 inhibitor (apremilast) were ineffective. Repeated skin biopsies excluded mycosis fungoides, confirming psoriasis; molecular analysis of T-cell receptor genes ruled out clonality. The axillary lymph node histology documented a dermatopathic lymphadenitis, often associated with chronic cutaneous inflammatory diseases. At an accurate morphological evaluation, features of HHV8-positive multicentric Castleman disease were observed. Moreover, in a few follicles, in situ mantle cell neoplasia was identified. The translocation t(11;14)(q13;q32), characteristic of mantle cell lymphoma, and the monoclonal IGH gene rearrangement were present. HHV8 DNA was identified on plasma sample. Multicentric Castleman disease in psoriatic patients is a rare event and it might be favored by the immunomodulatory treatment in longstanding psoriasis. Multicentric Castleman disease patients are predisposed to developing simultaneous or subsequent lymphoma. In situ mantle cell neoplasia often behaves indolently, although it may progress to overt mantle cell lymphoma. Rituximab achieved a good control of psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis for which he is currently on antibiotic therapy.

scholarly journals Multifocal Mantle Cell Lymphoma In Situ in the Setting of a Composite Lymphoma

2015 ◽  
Vol 143 (2) ◽  
pp. 274-282 ◽  
Author(s):  
Caroline Sloan ◽  
Qun-Bin Xiong ◽  
Anne Crivaro ◽  
Sharon Steinman ◽  
Adam Bagg
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Composite Lymphoma ◽  
Mantle Cell

Rare presentation of in situ mantle cell lymphoma.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e18566-e18566
Author(s):  
C. M. Hamm ◽  
R. Herriot
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Rare Presentation ◽  
Mantle Cell

scholarly journals In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior

Haematologica ◽  
2011 ◽  
Vol 97 (2) ◽  
pp. 270-278 ◽  
Author(s):  
A. Carvajal-Cuenca ◽  
L. F. Sua ◽  
N. M. Silva ◽  
S. Pittaluga ◽  
C. Royo ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Incidental Finding ◽  
Clinical Implications ◽  
Clinical Behavior ◽  
Mantle Cell

In-situ mantle cell lymphoma-a report of two cases

2007 ◽  
Vol 52 (2) ◽  
pp. 256-260 ◽  
Author(s):  
N Aqel ◽  
F Barker ◽  
K Patel ◽  
K N Naresh
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Mantle Cell

scholarly journals Identification on Mantle Cell Lymphoma Using CD20 and CD5 Coupled Upconversion Fluorescent Nanoprobes

2018 ◽  
Vol 2018 ◽  
pp. 1-12
Author(s):  
Mingkai Zhang ◽  
Yang Gao ◽  
Jialiang Wang ◽  
Zhanbo Liu ◽  
Zaishun Jin ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Fluorescence Imaging ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Upconversion Fluorescence ◽  
Mantle Cell

In order to determine a particular tumor cell via nanomaterials, we introduce the preparation of CD20 and CD5 coupled nanoprobes (denoted as CD20 and CD5 nanoprobes for convenience) and an application in identification of mantle cell lymphoma (MCL) from B-cell lymphoma. In this work, CD20 and CD5 nanoprobes were prepared by selectively oxidizing the carbon-carbon double bonds of oleate ligands on the surfaces of NaYF4:Yb3+,Tm3+ and NaYF4:Yb3+,Er3+ nanoparticles and, respectively, coupling carboxyl groups on the particles’ surfaces with CD20 and CD5 monoclonal antibodies through EDC/NHS crosslinking agents. After in situ hybridized Jeko-1 cells and Raji cells as a reference with CD20 and CD5 nanoprobes, in vitro double-color upconversion fluorescence imaging of Jeko-1 cells was demonstrated through visualization of blue and green fluorescence under a 980 nm laser excitation. Moreover, in vivo upconversion fluorescence imaging of the transplanted cancer model was also measured. These experimental results indicate that Jeko-1 cells have been specifically labeled by CD20 and CD5 nanoprobes. It is therefore concluded that CD20 and CD5 nanoprobes could be used to specially differentiate mantle cell lymphoma (MCL) from B-cell lymphoma.

Sign in / Sign up

Export Citation Format

Share Document